Skip to main content

A randomized, double-blind, placebo-controlled, multi-center study toevaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of orally administered GLPG3667 once daily for 24 weeks in adult subjects with dermatomyositis

Open
  • Protocol code: GLPG3667-CL-214
  • EudraCT code: _
  • Research group: Systemic Diseases
  • Service: Internal Medicine
  • Principal investigator:  Selva O'Callaghan, Albert
  • Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
  • Phase: Fase II